Kraig Biocraft Laboratories Sets New World Record for Largest Spider Silk Gene Insert into Silkworm
Kraig Biocraft Laboratories (OTCQB: KBLB) has achieved a groundbreaking scientific milestone by successfully engineering the largest known spider silk gene insert into silkworm, nearly doubling the previous record. This breakthrough, led by Research Manager Dr. Xiaoli Zhang, enables the creation of larger, more complex proteins with unique mechanical properties for incorporation into silk fibers.
The achievement represents a significant advancement in developing high-performance biomaterials with enhanced strength, flexibility, and performance potential. While focusing on this innovation, the company maintains its commitment to commercializing its current recombinant spider silk production strains for applications in performance textiles, defense, and industrial sectors.
The company emphasizes that the significance lies not in the size of the genetic insert but in the information it carries, potentially unlocking new possibilities in material performance. Kraig Labs continues to pursue a dual strategy of commercializing existing spider silk technology while investing in future innovations.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha raggiunto una pietra miliare scientifica innovativa ingegnerizzando con successo il più grande inserto genetico noto di seta di ragno in bachi da seta, quasi raddoppiando il precedente record. Questa scoperta, guidata dal Manager della Ricerca Dr. Xiaoli Zhang, consente la creazione di proteine più grandi e complesse con proprietà meccaniche uniche da incorporare nelle fibre di seta.
Il risultato rappresenta un significativo progresso nello sviluppo di biomateriali ad alte prestazioni con maggiore resistenza, flessibilità e potenziale di performance. Pur concentrandosi su questa innovazione, l'azienda mantiene il suo impegno a commercializzare le attuali ceppi di produzione di seta di ragno ricombinante per applicazioni in tessuti performanti, difesa e settori industriali.
L'azienda sottolinea che l'importanza non risiede nella dimensione dell'inserto genetico, ma nelle informazioni che porta, sbloccando potenzialmente nuove possibilità nelle prestazioni dei materiali. Kraig Labs continua a perseguire una strategia duale di commercializzazione della tecnologia esistente della seta di ragno mentre investe in future innovazioni.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha logrado un hito científico innovador al haber insertado con éxito el mayor gen conocido de seda de araña en gusanos de seda, casi duplicando el récord anterior. Este avance, liderado por la Gerente de Investigación, la Dra. Xiaoli Zhang, permite la creación de proteínas más grandes y complejas con propiedades mecánicas únicas para su incorporación en fibras de seda.
Este logro representa un avance significativo en el desarrollo de biomateriales de alto rendimiento con mayor resistencia, flexibilidad y potencial de rendimiento. Mientras se centra en esta innovación, la empresa mantiene su compromiso de comercializar sus cepas actuales de producción de seda de araña recombinante para aplicaciones en textiles de rendimiento, defensa y sectores industriales.
La empresa enfatiza que la importancia no radica en el tamaño del inserto genético, sino en la información que lleva, lo que potencialmente abre nuevas posibilidades en el rendimiento de los materiales. Kraig Labs continúa persiguiendo una estrategia dual de comercialización de la tecnología existente de seda de araña mientras invierte en innovaciones futuras.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 실크웜에 가장 큰 알려진 거미줄 유전자 삽입을 성공적으로 엔지니어링하여 이전 기록을 거의 두 배로 늘리는 획기적인 과학적 이정표를 달성했습니다. 이 혁신은 연구 관리자 샤오리 장 박사에 의해 주도되었으며, 독특한 기계적 특성을 가진 더 크고 복잡한 단백질을 실크 섬유에 통합할 수 있게 합니다.
이 성과는 향상된 강도, 유연성 및 성능 잠재력을 가진 고성능 바이오 소재 개발의 중요한 진전을 나타냅니다. 이 혁신에 집중하면서도 회사는 성능 섬유, 방어 및 산업 분야에서의 응용을 위해 현재의 재조합 거미줄 생산 균주를 상용화하는 데 대한 약속을 유지하고 있습니다.
회사는 중요한 점이 유전자 삽입의 크기보다는 그것이 전달하는 정보에 있다고 강조하며, 이는 물질 성능에서 새로운 가능성을 열 수 있습니다. Kraig Labs는 기존 거미줄 기술의 상용화와 미래 혁신에 대한 투자를 병행하는 이중 전략을 계속 추구하고 있습니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) a atteint une étape scientifique révolutionnaire en réussissant à insérer le plus grand gène de soie d'araignée connu dans des vers à soie, doublant presque le précédent record. Cette avancée, dirigée par la responsable de la recherche Dr. Xiaoli Zhang, permet la création de protéines plus grandes et plus complexes avec des propriétés mécaniques uniques pour leur incorporation dans des fibres de soie.
Cette réalisation représente un progrès significatif dans le développement de biomatériaux haute performance avec une résistance, une flexibilité et un potentiel de performance améliorés. Tout en se concentrant sur cette innovation, l'entreprise maintient son engagement à commercialiser ses souches actuelles de production de soie d'araignée recombinante pour des applications dans les textiles de performance, la défense et les secteurs industriels.
L'entreprise souligne que l'importance ne réside pas dans la taille de l'insertion génétique, mais dans les informations qu'elle contient, ouvrant potentiellement de nouvelles possibilités en matière de performance des matériaux. Kraig Labs continue de poursuivre une stratégie duale de commercialisation de la technologie existante de soie d'araignée tout en investissant dans de futures innovations.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat einen bahnbrechenden wissenschaftlichen Meilenstein erreicht, indem es erfolgreich das größte bekannte Gen für Spinnenseide in Seidenspinner eingefügt hat, was den vorherigen Rekord fast verdoppelt. Dieser Durchbruch, geleitet von der Forschungsleiterin Dr. Xiaoli Zhang, ermöglicht die Schaffung größerer, komplexerer Proteine mit einzigartigen mechanischen Eigenschaften zur Integration in Seidenfasern.
Dieser Erfolg stellt einen bedeutenden Fortschritt bei der Entwicklung von Hochleistungs-Biomaterialien mit verbesserter Stärke, Flexibilität und Leistungspotenzial dar. Während das Unternehmen sich auf diese Innovation konzentriert, bleibt es seinem Engagement für die Kommerzialisierung seiner aktuellen rekombinanten Spinnenseidenproduktionsstämme für Anwendungen in Performance-Textilien, Verteidigung und Industrie treu.
Das Unternehmen betont, dass die Bedeutung nicht in der Größe des genetischen Inserts liegt, sondern in den Informationen, die es trägt, was potenziell neue Möglichkeiten in der Materialleistung eröffnet. Kraig Labs verfolgt weiterhin eine duale Strategie zur Kommerzialisierung der bestehenden Spinnenseidentechnologie und investiert gleichzeitig in zukünftige Innovationen.
- Achieved world record for largest spider silk gene insert in silkworm
- Breakthrough enables creation of more advanced biomaterials
- Expanding potential applications in performance textiles, defense, and industrial sectors
- Accelerating commercialization of existing spider silk technology
- No immediate revenue impact mentioned
- Commercialization timeline remains undefined
- Technical achievement yet to demonstrate commercial viability
ANN ARBOR, Mich., March 24, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk biotechnology, today announced a groundbreaking scientific achievement in the development of high-performance biomaterials. Kraig Labs successfully engineered the largest known spider silk gene insert into silkworm—nearly doubling the previous record. This breakthrough represents a major step toward creating next-generation spider silk fibers with enhanced strength, flexibility, and performance potential.
The project was led by Dr. Xiaoli Zhang, the Company’s research manager, whose team continues to push the boundaries of genetic engineering for spider silk production.
"This milestone significantly expands the possibilities for spider silk technology," said Dr. Zhang. "By increasing the size of the inserted spider silk genes, we are unlocking the potential for new materials with properties beyond what is currently achievable. This breakthrough lays the foundation for the future of high-performance silk fibers."
While the sheer size of the genetic insert marks a scientific breakthrough, its real significance is not in its size but in the information this genetic packet carries. This allows for the creation of larger more complex proteins with unique mechanical properties for incorporation into the silk fibers. As Kraig Labs moves forward with this technology, the Company will explore the tremendous opportunities for increases in material performance these new larger packets allow.
This scientific accomplishment represents a bold step forward in material innovation and expands the possibilities of what can be achieved in material performance. Kraig Labs remains fully committed to the commercialization of its current recombinant spider silk production strains, even as it accelerates its development of more advanced materials. The Company is moving forward rapidly to advance the scale-up of its existing technologies, bringing spider silk fibers to market for applications in performance textiles, defense, and industrial sectors.
"Our mission is twofold: to commercialize our existing spider silk technology while continuously innovating for the future," said Company CEO and founder, Kim Thompson. "This record-setting genetic achievement underscores the depth of our research capabilities and demonstrates our long-term vision for creating even more advanced biomaterials. Dr. Zhang and her team have taken a critical step toward making the next generation of spider silk a reality."
Kraig Labs is currently accelerating its recombinant spider silk production, while also investing in the future of spider silk technology. The Company will continue to provide updates on both its commercialization efforts and its groundbreaking research.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ab1f7d4-8e0a-4ccb-8411-068ff1fa388a
FAQ
What is the significance of KBLB's new spider silk gene insert record?
How will KBLB's spider silk breakthrough impact commercial applications?
What markets is KBLB targeting with its spider silk technology?
Who led the record-breaking spider silk research at KBLB?
